Screening Method for Hiv Rt Inhibitors
    44.
    发明申请
    Screening Method for Hiv Rt Inhibitors 审中-公开
    Hiv Rt抑制剂的筛选方法

    公开(公告)号:US20080213810A1

    公开(公告)日:2008-09-04

    申请号:US11813817

    申请日:2006-02-06

    IPC分类号: C12Q1/48

    CPC分类号: C12Q1/48

    摘要: The present invention is directed to methods for identifying a specific class of inhibitors of HIV reverse transcriptase that act differently from known reverse transcriptase inhibitors. In particular, the invention is based on identifying inhibitors which have higher inhibitory activity in presence of a nucleoside triphosphate or pyrophosphate.

    摘要翻译: 本发明涉及用于鉴定与已知逆转录酶抑制剂不同的作用的特定类型的HIV逆转录酶抑制剂的方法。 特别地,本发明基于鉴定在核苷三磷酸或焦磷酸盐存在下具有较高抑制活性的抑制剂。

    Hiv Inhibiting 2-(4-Cyanophenylamino) Pyrimidine Oxide Derivatives
    45.
    发明申请
    Hiv Inhibiting 2-(4-Cyanophenylamino) Pyrimidine Oxide Derivatives 有权
    抑制2-(4-氰基苯基氨基)嘧啶氧化物衍生物

    公开(公告)号:US20080194602A1

    公开(公告)日:2008-08-14

    申请号:US11814958

    申请日:2006-02-20

    IPC分类号: C07D239/48 A61K31/505

    CPC分类号: C07D239/48

    摘要: HIV replication inhibitors of formula (I) a pharmaceutically acceptable addition salt; or a stereochemically isomeric form thereof, wherein R1 is halo; R2 and R3 each independently are C1-6alkyl. Pharmaceutical compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

    摘要翻译: 式(I)的HIV复制抑制剂药学上可接受的加成盐; 或其立体化学异构体形式,其中R 1是卤素; R 2和R 3各自独立地为C 1-6烷基。 含有这些化合物作为活性成分的药物组合物和制备这些化合物和组合物的方法。

    Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
    46.
    发明授权
    Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors 有权
    Broadspectrum取代羟吲哚磺酰胺HIV蛋白酶抑制剂

    公开(公告)号:US07199148B2

    公开(公告)日:2007-04-03

    申请号:US10524451

    申请日:2003-08-14

    CPC分类号: C07D493/04 C07D209/34

    摘要: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(═O)—, —O—C(═O)—, —NR8—C(═O)—, —O—C1-6alkanediyl-C(═O)—, —NR8—C1-6alkanediyl-C(═O)—, —S(═O)2—, —O—S(═O)2—, —NR8—S(═O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(═O), carboxyl, aminoC(═O), mono- or di(C1-4alkyl)aminoC(═O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; R5a and R5b is C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or C1-6alkyl, optionally substituted on one or more atoms; R5a and R5b may also be hydrogen, aryl, Het1, Het2; R6 is hydrogen or C1-6alkyl optionally substituted on one ore more carbon atoms. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.

    摘要翻译: 本发明涉及具有下式的化合物